Literature DB >> 9115290

Bioactive peptide design based on protein surface epitopes. A cyclic heptapeptide mimics CD4 domain 1 CC' loop and inhibits CD4 biological function.

T Satoh1, J M Aramini, S Li, T M Friedman, J Gao, A E Edling, R Townsend, U Koch, S Choksi, M W Germann, R Korngold, Z Huang.   

Abstract

The interaction between CD4 and major histocompatibility complex class II proteins provides a critical co-receptor function for the activation of CD4(+) T cells implicated in the pathogenesis of a number of autoimmune diseases and transplantation responses. A small synthetic cyclic heptapeptide was designed and shown by high resolution NMR spectroscopy to closely mimic the CD4 domain 1 CC' surface loop. This peptide effectively blocked stable CD4-major histocompatibility complex class II interaction, possessed significant immunosuppressive activity in vitro and in vivo, and strongly resisted proteolytic degradation. These results demonstrate the therapeutic potential of this peptide as a novel immunosuppressive agent and suggest a general strategy of drug design by using small conformationally constrained peptide mimics of protein surface epitopes to inhibit protein interactions and biological functions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9115290     DOI: 10.1074/jbc.272.18.12175

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Understanding and designing head-to-tail cyclic peptides.

Authors:  Diana P Slough; Sean M McHugh; Yu-Shan Lin
Journal:  Biopolymers       Date:  2018-03-12       Impact factor: 2.505

2.  Multistep tandem mass spectrometry for sequencing cyclic peptides in an ion-trap mass spectrometer.

Authors:  L C Ngoka; M L Gross
Journal:  J Am Soc Mass Spectrom       Date:  1999-08       Impact factor: 3.109

3.  Human leukocyte antigen-DQ8 transgenic mice: a model to examine the toxicity of aerosolized staphylococcal enterotoxin B.

Authors:  Chad J Roy; Kelly L Warfield; Brent C Welcher; Raoul F Gonzales; Tom Larsen; Julie Hanson; Chella S David; Theresa Krakauer; Sina Bavari
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

Review 4.  The apoptotic pathway as a therapeutic target in sepsis.

Authors:  Doreen E Wesche-Soldato; Ryan Z Swan; Chun-Shiang Chung; Alfred Ayala
Journal:  Curr Drug Targets       Date:  2007-04       Impact factor: 3.465

5.  Up to 9-day survival and control of thrombocytopenia following alpha1,3-galactosyl transferase knockout swine liver xenotransplantation in baboons.

Authors:  Karen Kim; Christian Schuetz; Nahel Elias; Gregory R Veillette; Isaac Wamala; Manish Varma; R Neal Smith; Simon C Robson; A Benedict Cosimi; David H Sachs; Martin Hertl
Journal:  Xenotransplantation       Date:  2012 Jul-Aug       Impact factor: 3.907

6.  Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites.

Authors:  Paris R Watson; Timothy W Craven; Xinting Li; Stephen Rettie; Parisa Hosseinzadeh; Fátima Pardo-Avila; Asim K Bera; Vikram Khipple Mulligan; Peilong Lu; Alexander S Ford; Brian D Weitzner; Lance J Stewart; Adam P Moyer; Maddalena Di Piazza; Joshua G Whalen; Per Jr Greisen; David W Christianson; David Baker
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

7.  Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vbeta use: a new paradigm for designer allogeneic blood and marrow transplantation.

Authors:  Thea M Friedman; Kira Goldgirsh; Stephanie A Berger; Jenny Zilberberg; Joanne Filicko-O'Hara; Neal Flomenberg; Michele Donato; Scott D Rowley; Robert Korngold
Journal:  Blood       Date:  2008-06-09       Impact factor: 22.113

8.  Computer applications for prediction of protein-protein interactions and rational drug design.

Authors:  Solène Grosdidier; Max Totrov; Juan Fernández-Recio
Journal:  Adv Appl Bioinform Chem       Date:  2009-11-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.